Johnson & Johnson (JNJ) Position Cut by Markston International LLC

Markston International LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,627 shares of the company’s stock after selling 1,945 shares during the period. Markston International LLC’s holdings in Johnson & Johnson were worth $10,004,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Pachira Investments Inc. increased its holdings in shares of Johnson & Johnson by 12.2% in the first quarter. Pachira Investments Inc. now owns 4,424 shares of the company’s stock valued at $551,000 after purchasing an additional 480 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI increased its holdings in shares of Johnson & Johnson by 0.5% in the first quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 114,681 shares of the company’s stock valued at $14,283,000 after purchasing an additional 544 shares during the period. Cedar Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 5.3% in the first quarter. Cedar Wealth Management LLC now owns 3,294 shares of the company’s stock valued at $410,000 after purchasing an additional 167 shares during the period. Usca Ria LLC increased its holdings in shares of Johnson & Johnson by 4.7% in the first quarter. Usca Ria LLC now owns 49,607 shares of the company’s stock valued at $6,179,000 after purchasing an additional 2,244 shares during the period. Finally, Willingdon Wealth Management increased its holdings in shares of Johnson & Johnson by 11.8% in the first quarter. Willingdon Wealth Management now owns 12,958 shares of the company’s stock valued at $1,614,000 after purchasing an additional 1,372 shares during the period. 65.90% of the stock is currently owned by institutional investors.

A number of brokerages have recently weighed in on JNJ. J P Morgan Chase & Co increased their price objective on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 16th. Citigroup assumed coverage on Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 target price on the stock. Jefferies Group set a $145.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a report on Tuesday, August 15th. BMO Capital Markets reaffirmed a “positive” rating and set a $152.00 target price (up from $145.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Finally, Royal Bank Of Canada raised their target price on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $144.59.

Johnson & Johnson (NYSE JNJ) traded down $0.97 during midday trading on Tuesday, hitting $139.01. The stock had a trading volume of 5,916,600 shares, compared to its average volume of 5,873,962. The stock has a market capitalization of $376,059.06, a P/E ratio of 19.60, a PEG ratio of 2.85 and a beta of 0.80. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.68 earnings per share. research analysts forecast that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.42%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

WARNING: “Johnson & Johnson (JNJ) Position Cut by Markston International LLC” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/12/05/johnson-johnson-jnj-position-cut-by-markston-international-llc.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit